Weekly cyclophosphamide, subcutaneous bortezomib and dexamethathasone (CyBorD) for initial treatment of transplant-eligible patients with multiple myeloma: experience of two transplant centresdoi:10.1038/s41409-020-01086-9Georgia J. McCaughanAnvita Verma...